Hypertrophic cardiomyopathy-associated mutations drive stromal activation via EGFR-mediated paracrine signaling.
Ewoldt JK. et al, (2024), Sci Adv, 10
Comparing the effects of chemical Ca2+ dyes and R-GECO on contractility and Ca2+ transients in adult and human iPSC cardiomyocytes.
Robinson P. et al, (2023), J Mol Cell Cardiol, 180, 44 - 57
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy
Margara F. et al, (2022), Scientific Reports, 12
Pathogenesis of Cardiomyopathy Caused by Variants in ALPK3, an Essential Pseudokinase in the Cardiomyocyte Nucleus and Sarcomere.
Agarwal R. et al, (2022), Circulation
Filamin C Cardiomyopathy Variants Cause Protein and Lysosome Accumulation
Agarwal R. et al, (2021), Circulation Research